目的: 建立了睫毛精华类化妆品中 5 种前列腺素类似物（比马前列素、拉坦前列素、曲伏前列素、他 氟前列素、他氟乙酰胺）的高效液相色谱测定方法及液相色谱 - 串联质谱确证分析方法。方法: 样品经甲 醇超声提取,采用 Agilent Poroshell 120 EC-C18 柱（4.6 mm×100 mm,2.7 μm）分离,以乙腈 - 水为流动相 梯度洗脱,二级阵列管检测器（DAD）在 210 nm 测定,外标法定量,采用液相色谱 - 串联质谱进行确证。 结果: 5 种前列腺素类似物在 0.1~25 μg·mL-1 范围内线性良好,相关系数（r2）均大于 0.999,方法检出浓 度（LOD）为 0.3~0.6 μg·g-1,三水平加标回收率为 93.2%~108.6%,相对标准偏差（RSD）为 0.60%~5.5%。结论: 该方法准确、快速、简便,适用于睫毛精华液化妆品中前列腺类似物的筛查。
Objective: To develop a method for the simple determination of five prostaglandins（bimatoprost, latanoprost,travoprost,tafluprost and tafluprost ethyl amide）in eyelash enhancing cosmetics using high performance liquid chromatography（HPLC）and liquid chromatography-tandem mass spectrometry（LC-MS/MS）. Method: The cosmetic samples were supersonically extracted with methanol and then separated on an Agilent Poroshell 120 EC-C18 column（4.6 mm×100 mm,2.7 μm）by gradient evolution with acetonitrile-water as mobile phases. The wavelength of detection was 210 nm and the external standard method was used for quantitation. The suspected samples were further verified by LC-MS/MS. Results: The five prostaglandins had a good linearity in the range of 0.1-25 μg·mL-1 with correlation coefficients（r2）larger than 0.999. The limits of detection（LODs） were between 0.3 and 0.6 μg·g-1.The spiked recoveries were 93.2% to 108.6% with the relative standard deviation (RSD) of 0.6% to 5.5%. Conclusion: The method is accurate，rapid and simple. It is suitable for the quality control in eyelash enhancing cosmetics.
[1] 刘颖,刘默,刘登.治疗青光眼的前列腺素 F2α 类似物的研究进展[J].天津药学,2007,19(2):48
LIU Y,LIU M,LIU D.The development of prostaglandin F2αanalogues as antiglaucomaagents[J].Tianjin Pharm,2007,19(2):48
[2] 蒲强红,吕秋菊,令红艳,等.治疗青光眼的前列腺素类药物[J].四川生理科学杂志,2008,30(4):175
PU QH,L QJ,LING HY,et al.Treatment of glaucoma:focus on prostaglandin analogues[J].Sichuan J Physiol Sci,2008,30(4):175
[3] 汪梦园,袁军,张慧芝.四种前列腺素类药物的降眼压疗效和耐受性对比研究[J].眼科新进展,2019,39(10):944
WANG MY,YUAN J,ZHANG HZ.Efficacy and tolerance of four prostaglandins in reducing intraocularpressure[J].Rec Adv Ophthalmol,2019,39(10):944
[4] TOSTI A,PAZZAGLIA M,VOUDOURIS S,et al.Hypertrichosis of the eyelashes caused by bimatoprost[J]. J Am Acad Dermatol, 2004.6(51):S149
[5] WOODSON S A.Latisse:empirical discovery yields treatment for sparse eyelashes[J].Nurs Womens Health,2009,13(3):243
[6] INOUE K,SHIOKAWA M,HIGA R,et al.Adverse periocular reactions to five types of prostaglandin analogs[J].Eye,2012,26: 1465
[7] HOLLO G.The side effects of the prostaglandin analogues[J]. Expert Opinion Drug Safety,2007,1(6):45
8 ALAGOZ G,BAYER A,BORAN C,et al．Comparison of ocular surface side effects of topical travoprost and bimatoprost[J]. Ophthalmologica,2008,222：161
[9] 化妆品安全技术规范 2015 年版[S].2015
Safety and Technical Standards forCosmetics 2015[S].2015
[10] Regulation(EC)No1223/2009 of the European Parliament and of the council[S].2009
[11] KUMAR SS,NATRAJ K,KHANA,et al.Development and validation of RP-HPLC method for estimation of bimatoprost in pharmaceutical dosage forms[J].J Pharm Res,2011,4(10):3733
[12] ZEZULA M,RUSZCZAK M,MARUSZAK W,et al.Development and validation of the stability indicating RP-UHPLC method for the determination of the chemical purity and assay of bimatoprost[J].J Pharm Biomed Anal,2019,174(10):348
[13] JOHNSON TV,GUPTA PK,VUDATHALA DK,et al.Thermal stability of bimatoprost,latanoprost,and travoprost under simulated daily use[J].J Ocul Pharmacol Ther,2011,27:51
[14] 潘晨,许勇,韩晶,等.高效液相色谱-串联质谱法测定睫毛增长液化妆品中的比马前列素[J].分析测试学报,2020,39(7):917
PAN C,XU Y,HAN J.et al.Determination of bimatoprost in eyelash enhancing cosmetics serumsby LC-MS/MS[J].J Instrum Anal,2020,39(7):917
[15] MAXEY KM,JOHNSON JL,BRECQUE JL.The Hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist[J].Survey Ophthalmol,2002,47(1):S34
[16] EMILIA M,DANIELA DO,CARMINE G,et al.High performance liquid chromatography tandem mass spectrometry measurement of bimatoprost,latanoprost and travoprost in eyelash enhancing cosmetic serums[J].Cosmetics,2016,3(4):2
